Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised, Double-blind, Parallel Group, 4-week Treatment, Adaptive Dose Finding, Multi-centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee

NCT00878501 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00878501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00878501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised, Double-blind, Parallel Group, 4-week Treatment, Adaptive Dose Finding, Multi-centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2009
Completion date
July 31, 2009
Enrollment
241 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

pain